Epimedin B ameliorates benzo[a]pyrene -induced C2C12 myotube atrophy through p53 signaling pathway
Cellular Signalling · 2027-01 · 149 · 112906
DOI: 10.1016/j.cellsig.2026.112906 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2027-01. Verfasst von Mengling Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Die Arbeit nennt 66 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Benzo[a]pyrene (BAP) is an established environmental carcinogen implicated in skeletal muscle atrophy. Epimedin B (Epi B), a major flavonoid component of Epimedium, possesses anti-inflammatory, anti-osteoporotic, and neuroprotective properties. However, the molecular mechanism underlying its protection against BAP-induced myotube atrophy remains largely elusive. METHODS: Transcriptomic profiling of BAP-treated C2C12 mouse myoblasts and network pharmacology-based target prediction were integrated to identify the key pathways underlying the ameliorative effect of Epi B against BAP-induced myotube atrophy. An in vitro model of myotube atrophy was established by treating C2C12 mouse myoblasts with 5 μM BAP. Myotube morphology and viability were evaluated using CCK-8 assay, Giemsa staining, and Desmin immunofluorescence. Mechanistic alterations were assessed by qRT-PCR, Western blotting, and flow cytometry. p53 knockdown experiments were performed to verify the role of the p53 pathway. RESULTS: Integrative analysis of transcriptomics and network pharmacology identified the p53 signaling pathway as a critical mediator of the protective effect of Epi B against BAP-induced myotube atrophy. BAP triggered oxidative stress, mitochondrial dysfunction, and suppression of myotube differentiation, accompanied by p53-mediated upregulation of p21 and BAX/BCL-2 ratio. Administration of 10 μM Epi B reversed these abnormalities by suppressing p53 activation, thereby reducing reactive oxygen species (ROS) production and apoptosis, restoring mitochondrial membrane potential, and ameliorating myotube atrophy. These findings were further corroborated by p53 knockdown experiments, which attenuated the protective effects of Epi B. CONCLUSION: These findings suggest that Epi B ameliorates BAP-induced myotube atrophy in C2C12 cells partly through p53 signaling pathway. This study provides novel mechanistic insights into BAP-induced sarcopenia and identifies potential therapeutic targets for intervention by Epi B.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- Department of Biochemistry, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: gzb@shutcm.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ma, M., Zheng, M., Qin, X., Xiao, K., & Gong, Z. (2027). Epimedin B ameliorates benzo[a]pyrene -induced C2C12 myotube atrophy through p53 signaling pathway. Cellular Signalling, 149, 112906. https://doi.org/10.1016/j.cellsig.2026.112906
Vancouver
Ma M, Zheng M, Qin X, Xiao K, Gong Z. Epimedin B ameliorates benzo[a]pyrene -induced C2C12 myotube atrophy through p53 signaling pathway. Cellular Signalling. 2027;149:112906. doi:10.1016/j.cellsig.2026.112906
BibTeX
@article{Ma2027,
author = {Ma, Mengling and Zheng, Minyi and Qin, Xiangnan and Xiao, Kefei and Gong, Zhangbin},
title = {Epimedin B ameliorates benzo[a]pyrene -induced C2C12 myotube atrophy through p53 signaling pathway},
journal = {Cellular Signalling},
year = {2027},
volume = {149},
pages = {112906},
doi = {10.1016/j.cellsig.2026.112906}
}
EUVIMED